Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents

Aspergillus species are the leading cause of invasive aspergillosis in immunocompromised hosts. The susceptibility of Aspergillus species to antifungal agents might be different. ABSTRACT Aspergillus species are a major cause of life-threatening invasive infections and noninvasive diseases. This study seeks to investigate the frequency of Aspergillus species among Iranian patients and their susceptibility to seven antifungals. In a cross-sectional study, 233 Aspergillus isolates were collected from 11 university hospitals in Iran between 2018 and 2021. Aspergillus isolates were identified based on colony morphology, microscopic characteristics, PCR-restriction fragment length polymorphism (RFLP), and sequencing of the beta-tubulin gene. The CLSI M38-A2 reference methodology was used for antifungal susceptibility testing of amphotericin B, voriconazole, posaconazole, itraconazole, luliconazole, isavuconazole, and caspofungin. Members of Aspergillus section Flavi (117/233, 50.2%), Aspergillus section Nigri (77/233, 33.1%), Aspergillus section Fumigati (21/233, 9%), Aspergillus section Terrei (14/233, 6%), Aspergillus pseudodeflectus (2/233, 0.85%), and Aspergillus melleus (2/233, 0.85%) were isolated from the samples. The lowest 0.25 MIC90 values for all isolates tested were for luliconazole (0.016 μg/mL) and isavuconazole (0.250 μg/mL), and the highest value was observed for itraconazole (≥ 8μg/mL). The 90% minimum effective concentration (MEC90) value for caspofungin was 0.125 μg/mL. MIC90 values for voriconazole, amphotericin B, and posaconazole were 1, 2, and 2 μg/mL, respectively. The non-wild-type species were presented for amphotericin B (3%), voriconazole (1.3%), posaconazole (2.6%), luliconazole (1.3%), isavuconazole (1.7%), and caspofungin (4.7%). Positive correlations in the MIC values of azole antifungals were observed, and using one azole increases the MIC value rates of other ones. None of the species were pan-azole resistant. Species of Aspergillus section Flavi were the most common Aspergillus species isolated from Iranian samples. Luliconazole, caspofungin, and isavuconazole present the most effective antifungal agents for treatment of infection due to Aspergillus species. Susceptibility tests should be performed frequently in each region for the best management of patients. IMPORTANCE Aspergillus species are the leading cause of invasive aspergillosis in immunocompromised hosts. The susceptibility of Aspergillus species to antifungal agents might be different. Azole-resistant species have emerged worldwide. Performing susceptibility testing in each region can help in the best management of patients. Here, we show the epidemiology and distribution of Aspergillus species in Iran and their susceptibility patterns for seven antifungal agents. The significant points of the present study are that species of Aspergillus section Flavi are the most prevalent Aspergillus species isolated from 11 university hospitals. Luliconazole, caspofungin, and isavuconazole were effective antifungal agents against all Aspergillus species.

[1]  Chih-Cheng Lai,et al.  COVID-19 associated with pulmonary aspergillosis: A literature review , 2020, Journal of Microbiology, Immunology and Infection.

[2]  M. Skov,et al.  Azole-Resistant Aspergillus fumigatus Among Danish Cystic Fibrosis Patients: Increasing Prevalence and Dominance of TR34/L98H , 2020, Frontiers in Microbiology.

[3]  E. Dannaoui,et al.  In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species , 2020, Journal of fungi.

[4]  J. Houbraken,et al.  Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China , 2020, Mycopathologia.

[5]  Eelco F. J. Meijer,et al.  Burden of serious fungal infections in the Netherlands , 2020, Mycoses.

[6]  A. Mahmoudabadi,et al.  The high efficacy of luliconazole against environmental and otomycosis Aspergillus flavus strains , 2020, Iranian journal of microbiology.

[7]  M. Fatahinia,et al.  The potency of luliconazole against clinical and environmental Aspergillus nigri complex , 2019, Iranian journal of microbiology.

[8]  S. Seyedmousavi,et al.  In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[9]  M. Faria,et al.  Aspergillus Species and Antifungals Susceptibility in Clinical Setting in the North of Portugal: Cryptic Species and Emerging Azoles Resistance in A. fumigatus , 2018, Front. Microbiol..

[10]  S. Seyedmousavi,et al.  Isolation and Characterization of Clinical Triazole Resistance Aspergillus fumigatus in Iran , 2018, Iranian journal of public health.

[11]  H. Badali,et al.  Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon? , 2018, Front. Microbiol..

[12]  R. Herbrecht,et al.  Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity. , 2018, Journal de mycologie medicale.

[13]  H. Badali,et al.  In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex , 2018, Mycoses.

[14]  W. Melchers,et al.  Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs , 2018, The Journal of antimicrobial chemotherapy.

[15]  A. Zarei Mahmoudabadi,et al.  Luliconazole, an alternative antifungal agent against Aspergillus terreus. , 2017, Journal de mycologie medicale.

[16]  M. Ghannoum,et al.  Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard , 2017, Journal of Clinical Microbiology.

[17]  A. Chowdhary,et al.  Clinical implications of globally emerging azole resistance in Aspergillus fumigatus , 2016, Philosophical Transactions of the Royal Society B: Biological Sciences.

[18]  H. Badali,et al.  High prevalence of clinical and environmental triazole-resistant Aspergillus fumigatus in Iran: is it a challenging issue? , 2016, Journal of medical microbiology.

[19]  M. Abastabar,et al.  PCR-RFLP on β-tubulin gene for rapid identification of the most clinically important species of Aspergillus. , 2015, Journal of microbiological methods.

[20]  W. Ko,et al.  Azole‐resistant Aspergillus fumigatus isolates carrying TR34/L98H mutations in Taiwan , 2015, Mycoses.

[21]  G. Sabz,et al.  Evaluation of nested PCR in diagnosis of fungal rhinosinusitis , 2015, Iranian journal of microbiology.

[22]  A. Colombo,et al.  Cryptic and Rare Aspergillus Species in Brazil: Prevalence in Clinical Samples and In Vitro Susceptibility to Triazoles , 2014, Journal of Clinical Microbiology.

[23]  J. Meis,et al.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[24]  J. Turnidge,et al.  Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for Aspergillus spp. for the CLSI M38-A2 Broth Microdilution Method , 2013, Antimicrobial Agents and Chemotherapy.

[25]  W. Melchers,et al.  Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus , 2012, PloS one.

[26]  J. Pemán,et al.  Antifungal Susceptibility Testing of Filamentous Fungi , 2012, Current Fungal Infection Reports.

[27]  M. Ghannoum,et al.  Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document) , 2011, Antimicrobial Agents and Chemotherapy.

[28]  M. Arendrup,et al.  Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. , 2011, Medical mycology.

[29]  A. Alborzi,et al.  Determining the incidence of aspergillosis after liver transplant. , 2010, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[30]  J. Turnidge,et al.  Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document) , 2010, Journal of Clinical Microbiology.

[31]  B. Alexander,et al.  Molecular Identification of Aspergillus Species Collected for the Transplant-Associated Infection Surveillance Network , 2009, Journal of Clinical Microbiology.

[32]  D. Denning,et al.  Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure , 2009, Emerging infectious diseases.

[33]  A. Alborzi,et al.  Molecular diagnosis of Aspergillus endocarditis after cardiac surgery. , 2009, Journal of medical microbiology.

[34]  W. Melchers,et al.  Academic Editor: Chris Kibbler, Royal Free Hospital London, United Kingdom , 2007 .

[35]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[36]  T. Peláez,et al.  Outdoor environmental levels of Aspergillus spp. conidia over a wide geographical area. , 2006, Medical mycology.

[37]  M. Dierich,et al.  Epidemiology and outcome of infections due to Aspergillus terreus: 10‐year single centre experience , 2005, British journal of haematology.